Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.45 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2382836 | 0.93 | TRPV1 (0.44) | TRPV1NR2E1LMNAMAPTMAPK10 | |
| SCHEMBL2381536 | 0.92 | TRPV1 (0.43) | TRPV1NR2E1LMNAMAPTMAPK10 | |
| SCHEMBL2383751 | 0.92 | TRPV1 (0.43) | TRPV1NR2E1LMNAMAPTMAPK10 | |
| SCHEMBL2421551 | 0.92 | TRPV1 (0.43) | TRPV1NR2E1MAPK10HSD17B10 | |
| SCHEMBL5572916 | 0.92 | TRPV1 (0.45) | TRPV1NR2E1LMNAMAPTMAPK10 | |
| SCHEMBL2383522 | 0.91 | TRPV1 (0.42) | TRPV1NR2E1LMNAMAPTMAPK10 | |
| SCHEMBL12250917 | 0.90 | TRPV1 (0.42) | TRPV1NR2E1LMNAMAPTMAPK10 | |
| SCHEMBL12250987 | 0.90 | TRPV1 (0.44) | TRPV1NR2E1 | |
| SCHEMBL2382649 | 0.90 | TRPV1 (0.40) | TRPV1NR2E1LMNAMAPTMAPK10 | |
| SCHEMBL2382957 | 0.89 | TRPV1 (0.41) | TRPV1NR2E1LMNAMAPTMAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | claimed |
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | TIE1, TEK, KDR | TRPV1 4108/4885NR2E1 2125/4885LMNA 2968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.